LillyOncMed· @LillyOncMed · X·· 2 天前评分60
正文 · 原文
#ESMO2026 attendees: We invite you to explore real-world data on 3-month persistence and adherence to adjuvant abemaciclib in high-risk HR+, HER2- EBC: from ABSIDE-S. ePoster 1933eP View program details here: https://t.co/lJvrvDTCFD #BCSM #EBC https://t.co/GVUQhkPfo3
热度 3 · 3 赞 · 0 回复 · 0 转发
来源：LillyOncMed · x.com